Drug prices: the US against Germany and Europe
Medicines that cost many times more in the US — with the official prices from Germany, Switzerland, Austria and the Netherlands, and what an insured patient in Germany pays.
| Medicine | Unit | United States | Germany | Switzerland | Austria | Netherlands | German patient pays | Details |
|---|---|---|---|---|---|---|---|---|
| EpiPen | 2 auto-injectors | ~$225 (generic, pharmacy cost) | €147.12 statutory ceiling | CHF 109.30 | €121.10 (2 × €60.55, excl. VAT) | €96.94 (2 × €48.47) | €10 co-payment | Read the article → |
| Insulin (Humalog) | one 10 mL vial | $63.55 (pharmacy cost) | no official price list | CHF 38.65 | €27.28 (excl. VAT) | €17.87 | at most €10 per pack | Read the article → |
| Salbutamol inhaler | 200 doses | no like-for-like figure (Combivent: ~$497) | €18.78 (Ventolin; ceiling €21.62) | CHF 13.60 | €5.50 (Sultanol, excl. VAT) | €3.24 | €5 co-payment | Read the article → |
| Ozempic | one 1 mg pen (a month) | $995.82 (pharmacy cost) | no official price list | CHF 106.20 | €104.35 (excl. VAT) | €107.98 | €5–€10 for type 2 diabetes | Read the article → |
| Mounjaro | by strength | ~$1,112 a month (list price) | €807.84 for 3 × 5 mg pens (G-BA) | CHF 223.80–388.40 per pen | not in the reimbursement code | €176.58–433.82 per pen | co-payment for type 2 diabetes; full price for weight loss | Read the article → |
| Wegovy | maintenance dose | $1,349 per 4-week pack (list price) | not covered, no official price list | CHF 176.95 per pen | not in the reimbursement code | €184.35 per pen | full price | Read the article → |
| Eliquis | 5 mg, 30 days | $346 (list); Medicare $231 | no statutory ceiling | CHF 80.10 (56 tablets) | €77.55 (60 tablets, excl. VAT) | €1.12 per tablet | €5–€10 per pack | Read the article → |
| Jardiance | 10 mg, 30 days | Medicare $197; pharmacy cost ~$336 | no statutory ceiling | CHF 59.30 (30 tablets) | €46.70 (30 tablets, excl. VAT) | €1.41 per tablet | €5–€10 per pack | Read the article → |
| Xarelto | 20 mg, 30 days | Medicare $197 (2026); pharmacy cost ~$586 | no statutory ceiling for 20 mg | CHF 33.40 (28 tablets) | €41.35 (28 tablets, excl. VAT) | €34.65 (28 tablets) | €5–€10 per pack | Read the article → |
| Januvia | 100 mg, 30 days | Medicare $113; pharmacy cost ~$317 | €62.71 (28 tablets; ceiling €21.10) | CHF 44.80 (28 tablets) | generic €7.00 (28 tablets, excl. VAT) | €17.05 (28 tablets) | co-payment, plus any amount above the ceiling | Read the article → |
| Farxiga (Forxiga) | 10 mg, 30 days | Medicare $178.50; pharmacy cost ~$362 | no statutory ceiling | CHF 56.90 (28 tablets) | €47.70 (28 tablets, excl. VAT) | €39.51 (30 tablets) | €5–€10 per pack | Read the article → |
| Entresto | 97/103 mg, 30 days | Medicare $295 (2026); pharmacy cost ~$696 | no statutory ceiling | CHF 130.25 (56 tablets) | €140.85 (56 tablets, excl. VAT) | €115.81 (56 tablets) | €5–€10 per pack | Read the article → |
| Enbrel | 4 pens of 50 mg | $8,565 (list); Medicare ~$2,335 | €862.63 statutory ceiling | CHF 455.15 (2 pens) | €606.50 (excl. VAT) | €550.35 | €10 co-payment | Read the article → |
| Stelara | one 45 mg syringe | ~$14,937 (pharmacy cost); Medicare ~$4,490 | reference-price group created, amount pending | CHF 1,540.15 | €783.15 (excl. VAT) | €1,593.96 | €10 co-payment | Read the article → |
| Imbruvica | 420 mg, 30 days | Medicare $9,319 | no statutory ceiling | CHF 4,494.50 (28 tablets) | €4,934.75 (28 tablets, excl. VAT) | €5,595.93 (30 tablets) | €10 co-payment | Read the article → |
| NovoLog (NovoRapid) | one 10 mL vial | ~$69 (pharmacy cost); Medicare max. $35/month | no statutory ceiling | CHF 37.90 | €28.10 (excl. VAT) | €16.47 | at most €10 per pack | Read the article → |
| Trelegy Ellipta | one inhaler (30 doses) | ~$669 (pharmacy cost); Medicare from 2027 $175 | no statutory ceiling | CHF 76.80 | €69.45 (excl. VAT) | €54.45 | at most €10 per pack | Read the article → |
| Breo Ellipta (Relvar) | one inhaler (30 doses) | ~$390 (pharmacy cost), generic ~$229; Medicare from 2027 $67 | €34.46 statutory ceiling (Relvar €36.44) | CHF 44.70 | €40.85 (excl. VAT) | €29.94 | co-payment + €1.98 above the ceiling for Relvar | Read the article → |
| Linzess (Constella) | 290 mcg, 28 capsules | $282.48/month (list); Medicare from 2027 $136 | no statutory ceiling, no official price | CHF 73.25 | €71.00 (excl. VAT) | €51.88 | — | Read the article → |
| Xifaxan (rifaximin) | 550 mg, 56 tablets | $2,696 for 30 days (2024 list); Medicare from 2027 $1,000 | no statutory ceiling, no official price | CHF 298.95 | not listed | €296.82 | — | Read the article → |
| Vraylar (Reagila) | 1.5–6 mg, 28 capsules | $1,594.82 for 30 days (list); Medicare from 2027 $770 | no statutory ceiling | CHF 112.65 | €76.75 (excl. VAT) | €88.20 (3 mg) | — | Read the article → |
| Tradjenta (Trajenta) | 5 mg, 28–30 tablets | ~$504 for 30 tablets (pharmacy cost); Medicare from 2027 $78 | no statutory ceiling | CHF 56.45 (30 tablets) | €47.45 (30 tablets, excl. VAT) | €32.67 (28 tablets) | — | Read the article → |
| Janumet | 50/1000 mg, 56 tablets | ~$317 for 60 tablets (pharmacy cost), generic ~$151; Medicare from 2027 $80 | €25.31 statutory ceiling (Janumet €47.75) | CHF 41.30 | generic only: €7.85 (60 tablets, excl. VAT) | €20.39 | co-payment + €22.44 above the ceiling for Janumet | Read the article → |
| Otezla (apremilast) | 30 mg, 56 tablets | $5,589.89 for 60 tablets (list); Medicare from 2027 $1,650 | no statutory ceiling | CHF 334.85 (generic CHF 259.85) | €467.35 (generic €134.80, excl. VAT) | €457.44 (generic from €207.10) | — | Read the article → |
| Xtandi (enzalutamide) | 40 mg, 112 tablets | $15,352.94 for 120 × 40 mg (list); Medicare from 2027 $7,004 | no statutory ceiling | CHF 3,137.65 | €2,623.25 (excl. VAT) | €3,146.79 | — | Read the article → |
| Ofev (nintedanib) | 150 mg, 60 capsules | $12,622 for 30 days (2024 list), generic ~$723; Medicare from 2027 $6,350 | no statutory ceiling | CHF 1,577.15 (generic from CHF 295.65) | €2,268.90 (generic from €450.65, excl. VAT) | €2,226.88 (generic €1,397.38) | — | Read the article → |
| Ibrance (palbociclib) | 21 tablets (one 28-day cycle) | $15,741 for 30 days (2024 list); Medicare from 2027 $7,871 | no statutory ceiling | CHF 2,162.80 | €2,063.20 (excl. VAT) | €1,624.93 | — | Read the article → |
| Calquence (acalabrutinib) | 100 mg, 60 tablets | $14,228 for 30 days (2024 list); Medicare from 2027 $8,600 | no statutory ceiling | CHF 4,745.45 | €5,365.15 (excl. VAT) | €4,930.69 | — | Read the article → |
| Pomalyst (Imnovid) | 4 mg, 21 capsules (one cycle) | $21,744 for 30 days (2024 list); Medicare from 2027 $8,650 | €2,295.30 statutory ceiling (Imnovid €9,109.45) | CHF 7,250.95 (generic CHF 3,029.70) | generics only: from €354.00 (excl. VAT) | €235.70 per capsule | €10 co-payment; + €6,814.15 above the ceiling for Imnovid | Read the article → |
| Austedo XR (deutetrabenazine) | 12–48 mg, 30 tablets | $6,623 for 30 days (2024 list); Medicare from 2027 $4,093 | no price yet (EU authorisation 1/2026) | not listed | not listed | not listed | — | Read the article → |
Price concepts differ: US = pharmacy acquisition cost (CMS NADAC) or the maker's list price; Germany = statutory ceiling or pharmacy price; Switzerland = public price incl. VAT; Austria = social-insurance price excl. VAT (for drugs under a price model the effective price may be lower); Netherlands = average pharmacy price. Sources and dates are in each article. Cost information, not medical advice.
Open data: the official prices on this page as CSV (Q4 2026 edition, extended on November 9, 2026; column "as_of" = state of the source, for Switzerland the retrieval state of the Spezialitätenliste). Licence for our compilation: CC BY 4.0, attribution "Wellness Vision, wellnessvision.health". Archived copy with a permanent DOI: 10.5281/zenodo.24200714 (Zenodo; the same rows without the 32 Dutch rows, because medicijnkosten.nl does not permit commercial use). How to cite: Wellness Vision (2026), Official drug prices: United States, Germany, Switzerland — Q4 2026 edition, Zenodo, https://doi.org/10.5281/zenodo.24200714. The raw data belong to the agencies named; Austrian reimbursement-code data are not included because of their terms of use. We publish the file quarterly as a new edition; every row keeps its as-of date. Changes: on November 5, 2026 we added 47 rows for the ten drugs with a Medicare-negotiated price (Eliquis to NovoLog; US, Germany, Switzerland, Netherlands); the 23 earlier rows are unchanged. On November 6 and 9, 2026 we added 13 and 39 rows for 14 drugs from the second round of negotiations (Trelegy to Austedo). The first version of this edition was identical in content to the October 2026 file.